656 related articles for article (PubMed ID: 36360174)
1. Human Induced Pluripotent Stem Cell Phenotyping and Preclinical Modeling of Familial Parkinson's Disease.
Kim J; Daadi EW; Oh T; Daadi ES; Daadi MM
Genes (Basel); 2022 Oct; 13(11):. PubMed ID: 36360174
[TBL] [Abstract][Full Text] [Related]
2. Alpha-synuclein dynamics in induced pluripotent stem cell-derived dopaminergic neurons from a Parkinson's disease patient (PARK4) with SNCA triplication.
Fukusumi H; Togo K; Sumida M; Nakamori M; Obika S; Baba K; Shofuda T; Ito D; Okano H; Mochizuki H; Kanemura Y
FEBS Open Bio; 2021 Feb; 11(2):354-366. PubMed ID: 33301617
[TBL] [Abstract][Full Text] [Related]
3. Modeling Parkinson's disease with induced pluripotent stem cells harboring α-synuclein mutations.
Singh Dolt K; Hammachi F; Kunath T
Brain Pathol; 2017 Jul; 27(4):545-551. PubMed ID: 28585381
[TBL] [Abstract][Full Text] [Related]
4. Induced pluripotent stem cells: a tool for modeling Parkinson's disease.
Bose A; Petsko GA; Studer L
Trends Neurosci; 2022 Aug; 45(8):608-620. PubMed ID: 35667922
[TBL] [Abstract][Full Text] [Related]
5. Genes Implicated in Familial Parkinson's Disease Provide a Dual Picture of Nigral Dopaminergic Neurodegeneration with Mitochondria Taking Center Stage.
Franco R; Rivas-Santisteban R; Navarro G; Pinna A; Reyes-Resina I
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33924963
[TBL] [Abstract][Full Text] [Related]
6. Pluripotent Stem Cell Derived Neurons as In Vitro Models for Studying Autosomal Recessive Parkinson's Disease (ARPD): PLA2G6 and Other Gene Loci.
Gopurappilly R
Adv Exp Med Biol; 2021; 1347():115-133. PubMed ID: 33990932
[TBL] [Abstract][Full Text] [Related]
7. Modeling Parkinson's Disease Using Patient-specific Induced Pluripotent Stem Cells.
Li H; Jiang H; Zhang B; Feng J
J Parkinsons Dis; 2018; 8(4):479-493. PubMed ID: 30149462
[TBL] [Abstract][Full Text] [Related]
8. Generation of an induced pluripotent stem cell line (GIBHi004-A) from a Parkinson's disease patient with mutant DJ-1/PARK7 (p.L10P).
Li Y; Ibañez DP; Fan W; Zhao P; Chen S; Md Abdul M; Jiang Y; Fu L; Luo Z; Liu Z; Yang Y; Guo J; Volpe G; Kanwal S; Wang D; Tang B; Li W
Stem Cell Res; 2020 Jul; 46():101845. PubMed ID: 32534165
[TBL] [Abstract][Full Text] [Related]
9. The multifaceted role of LRRK2 in Parkinson's disease: From human iPSC to organoids.
Oun A; Sabogal-Guaqueta AM; Galuh S; Alexander A; Kortholt A; Dolga AM
Neurobiol Dis; 2022 Oct; 173():105837. PubMed ID: 35963526
[TBL] [Abstract][Full Text] [Related]
10. Parkinson's disease: an update on preclinical studies of induced pluripotent stem cells.
Valadez-Barba V; Juárez-Navarro K; Padilla-Camberos E; Díaz NF; Guerra-Mora JR; Díaz-Martínez NE
Neurologia (Engl Ed); 2023; 38(9):681-694. PubMed ID: 37858889
[TBL] [Abstract][Full Text] [Related]
11. Parkinson's disease in a dish - Using stem cells as a molecular tool.
Badger JL; Cordero-Llana O; Hartfield EM; Wade-Martins R
Neuropharmacology; 2014 Jan; 76 Pt A():88-96. PubMed ID: 24035919
[TBL] [Abstract][Full Text] [Related]
12. Recent Advances in the Treatment of Genetic Forms of Parkinson's Disease: Hype or Hope?
Cavallieri F; Cury RG; Guimarães T; Fioravanti V; Grisanti S; Rossi J; Monfrini E; Zedde M; Di Fonzo A; Valzania F; Moro E
Cells; 2023 Feb; 12(5):. PubMed ID: 36899899
[TBL] [Abstract][Full Text] [Related]
13. Establishment of induced pluripotent stem cell lines derived from Parkinson's disease Mexican patients: A sporadic (UNAMi002-A) and a familial (UNAMi003-A) case carrying a mutation in PINK1.
Flores-Ponce X; López-Ornelas A; Escobedo-Avila I; Rodríguez-Violante M; Dávila-Ortiz de Montellano D; Cervantes-Arriaga A; Monroy-Jaramillo N; Campos-Romo A; Velasco I
Stem Cell Res; 2024 Apr; 76():103337. PubMed ID: 38359473
[TBL] [Abstract][Full Text] [Related]
14. Induced pluripotent stem cell (iPSC)-derived dopaminergic models of Parkinson's disease.
Beevers JE; Caffrey TM; Wade-Martins R
Biochem Soc Trans; 2013 Dec; 41(6):1503-8. PubMed ID: 24256244
[TBL] [Abstract][Full Text] [Related]
15. Surprising behavioral and neurochemical enhancements in mice with combined mutations linked to Parkinson's disease.
Hennis MR; Marvin MA; Taylor CM; Goldberg MS
Neurobiol Dis; 2014 Feb; 62():113-23. PubMed ID: 24075852
[TBL] [Abstract][Full Text] [Related]
16. Back and to the Future: From Neurotoxin-Induced to Human Parkinson's Disease Models.
Airavaara M; Parkkinen I; Konovalova J; Albert K; Chmielarz P; Domanskyi A
Curr Protoc Neurosci; 2020 Mar; 91(1):e88. PubMed ID: 32049438
[TBL] [Abstract][Full Text] [Related]
17. Reprint of: revisiting oxidative stress and mitochondrial dysfunction in the pathogenesis of Parkinson disease-resemblance to the effect of amphetamine drugs of abuse.
Perfeito R; Cunha-Oliveira T; Rego AC
Free Radic Biol Med; 2013 Sep; 62():186-201. PubMed ID: 23743292
[TBL] [Abstract][Full Text] [Related]
18. Genetic animal models of Parkinson's disease.
Dawson TM; Ko HS; Dawson VL
Neuron; 2010 Jun; 66(5):646-61. PubMed ID: 20547124
[TBL] [Abstract][Full Text] [Related]
19. Dopaminergic neurodegeneration induced by Parkinson's disease-linked G2019S LRRK2 is dependent on kinase and GTPase activity.
Nguyen APT; Tsika E; Kelly K; Levine N; Chen X; West AB; Boularand S; Barneoud P; Moore DJ
Proc Natl Acad Sci U S A; 2020 Jul; 117(29):17296-17307. PubMed ID: 32631998
[TBL] [Abstract][Full Text] [Related]
20. LRRK2 at the Crossroad of Aging and Parkinson's Disease.
Hur EM; Lee BD
Genes (Basel); 2021 Mar; 12(4):. PubMed ID: 33805527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
